MIRM Stock Forecast & Price Target

Mirum Pharmaceuticals is a promising company in the biopharmaceutical industry with a strong pipeline of treatments for rare and orphan diseases. The company has three approved medicines and is on track to potentially receive approval for Livmarli in additional indications in the near future. Positive data from the ongoing trials for maralixibat and volixibat support the company's potential for strong revenue growth in the coming years. However, there are regulatory risks to consider, mainly with regards to the potential delay of the volixibat NDA for PSC. Overall, Mirum Pharmaceuticals is well-positioned for success in the rare disease market, but investors should monitor regulatory developments closely.

Mirum Pharmaceuticals is facing challenges from FDA feedback on a potential NDA for volixibat in the PSC indication, which could potentially delay a submission until 1H27. Additionally, the company has a negative net loss which is projected to continue into 2027. This, coupled with the recent termination of the revenue interest purchase agreement, could lead to financial struggles for the company. Management's plans to use the Breakthrough Therapy Designation for volixibat to engage with the FDA and lower the price target for the stock in the next 12 months also indicates a potential struggle for the company in achieving profitability and success with this drug.